{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "WEAV",
  "name": "Weave Communications, Inc.",
  "url": "https://orbyd.app/dossiers/WEAV/",
  "json_url": "https://orbyd.app/dossiers/WEAV.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": "LOW",
  "archetype": {
    "code": "a3",
    "n": 3
  },
  "current_thesis": "Beaten-down vertical-SaaS front-office platform for healthcare SMBs, down ~36% YTD and basing off the $4.24 low, repositioning around AI-receptionist monetization (TrueLark, 2025). Still a ~17% grower with GAAP losses, so the re-rate is optionality not yet in the numbers; a reclaim of the $8.28 52-week high with AI-revenue proof is the trigger, and the ~Aug 6 Q2 print is the catalyst.",
  "invalidation_trigger": "A weekly close below $6.00 breaks the recovery base off the April $4.24 low and voids the AI-monetization re-rating setup; a Q2 print (~Aug 6) showing revenue growth decelerating under 15% with no AI-revenue disclosure is the secondary break.",
  "catalyst_date": "2026-08-06",
  "outcome": "INVALIDATED",
  "outcome_date": "2026-08-07",
  "invalidation_fired": true,
  "themes": [
    "managed-care-health-services"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Q2 2026 earnings ~2026-08-06 (est.) — binary event; hold off on fresh size into the print.",
    "Price/technical anchors: spot ~$7.34 (2026-07-17), 52-week range $4.24–$8.28, market cap ~$584M, down ~36% YTD.",
    "Entire re-rate thesis hinges on AI/TrueLark revenue appearing in the P&L — watch the Q2 disclosure specifically.",
    "Fundamentals through Q1 2026: revenue $65.5M +17.4% YoY, GAAP EPS -$0.07 (miss), FY2026 guide $275–278M, FY2025 FCF $12.9M.",
    "Not an accelerating momentum name yet — the tradable entry is a confirmed $8.28 breakout, not the current $6–$8 chop."
  ],
  "body_markdown": "## Current Thesis\n\nWeave runs a vertical-SaaS front-office platform for healthcare SMBs — dental, optometry, veterinary, med spa and primary care — bundling phones, texting, scheduling, payments and reviews in one system. Shares trade ~$7.34 (2026-07-17) at a ~$584M cap, down roughly 36% YTD and basing off an April 52-week low of $4.24. The narrative an investor is buying here is not the steady 17% grower it already is; it is the option that AI-receptionist automation — acquired through TrueLark in 2025 and now monetized by location and consumption rather than per seat — reaccelerates growth and re-rates a name the market left for dead. That option is real but absent from the numbers so far. Q1 2026 (reported May) delivered $65.5M revenue, +17.4% YoY, yet GAAP EPS of -$0.07 missed and sell-side trimmed targets $2–3. Treat this as a base-building, show-me setup that still needs a breakout to become a momentum trade.\n\n## Bull Case\n\n- **Durable execution**: 17 straight quarters of beating its own revenue guide through Q1 2026 ($65.5M, +17.4% YoY). FY2025 revenue $239M, +17% (reported 2026-02-18).\n- **Margin and cash inflection**: Q4 2025 gross margin 73.3% (FY 72.7%), Q4 operating income a record $2.3M (3.6% margin), FY2025 free cash flow $12.9M, +24% YoY — the model self-funds.\n- **AI monetization optionality**: TrueLark AI receptionist plus a unified inbox to be sold as add-on modules priced by location/consumption rather than per seat, layering new revenue on the ~$275M base (FY2026 guide raised to $275–278M at the Q1 print).\n- **Distribution flywheel**: authorized integrations keep widening the wedge — the Elation Health EHR integration announced 2026-07-17 extends reach into primary-care practices beyond the dental core.\n- **Analyst floor**: consensus Buy, average target ~$8.93–$9.00 (range $8–$10) against ~$7.34 spot, ~20–30% implied upside even after target cuts.\n\n## Bear Case\n\n- **Growth is steady, not accelerating**: ~17% has held for six-plus quarters (Q4 2025 +17%, Q1 2026 +17.4%). The tape shows no AI-driven reacceleration yet; the re-rate thesis rests on numbers that have not printed.\n- **Still GAAP-unprofitable**: Q1 2026 diluted EPS -$0.07 missed consensus; a money-losing small-cap re-rates violently on any rate or risk-off shift.\n- **Crowded AI-receptionist field**: TrueLark competes with Viva AI and a wave of vertical dental/med-spa AI front-desk entrants; pricing power on the module is unproven and commoditization risk is live.\n- **Heavy YTD damage**: down ~36% YTD with a $4.24 spring low; the year's holders sit underwater and rallies into resistance keep meeting supply.\n- **Trimmed targets**: sell-side cut average price targets $2–3 on softer margin assumptions; the marginal analyst is getting less constructive.\n\n## Setup & Price Structure\n\n- Spot ~$7.34 (2026-07-17); 52-week range $4.24–$8.28; market cap ~$584M.\n- The stock has recovered hard off the April $4.24 low and now coils just under the $8.28 52-week high — a base pressed directly against resistance.\n- The clean momentum trigger is a decisive close and hold above $8.28, which reclaims the high and puts price in fresh-high territory with no overhead supply.\n- A rejection here keeps it range-bound roughly $6–$8; the recovery structure is the higher-low sequence off $4.24, and losing it re-opens the downside.\n- This is a MATURING, basing profile rather than an accelerating one — the narrative-momentum entry is the $8.28 breakout, and the current range is a waiting game.\n\n## Catalyst Calendar (next 30 days)\n\n- No FDA/PDUFA date, index event, or known lockup in the window.\n\n## Elapsed catalysts\n\n- **~2026-08-06 (est.)** — Q2 2026 earnings. Guided $67.2–68.2M revenue and non-GAAP operating income $10.5–13.5M. The binary question: whether AI/TrueLark revenue is quantified and whether growth holds ≥17%. Binary risk — avoid fresh size into the print. *(passed 3d ago)*\n- **Ongoing** — integration/partnership drip. The Elation Health integration landed 2026-07-17; further authorized-integration announcements are the between-quarters narrative fuel. *(passed 23d ago)*\n\n## What Would Change Our Mind\n\n- **Bull confirmation**: a weekly close above $8.28 on expanding volume, ideally with the Q2 call quantifying AI-receptionist revenue — that turns the option into a trend and justifies pressing.\n- **Bear confirmation**: a weekly close below $6.00 breaks the recovery base off the $4.24 low and voids the re-rating setup; a Q2 print with growth under 15% and no AI-revenue disclosure would confirm dead money.\n- **Theme risk**: AI-receptionist pricing collapsing toward free/commodity — bundled by an EHR or a larger platform — flips the enterprise-AI-software theme to SATURATED for this name.\n\n## Correlation Notes\n\n- Trades as a small-cap, GAAP-unprofitable vertical SaaS: high beta to IWM (Russell 2000) and IGV (software), rate-sensitive given the long-duration cash-flow profile.\n- Detached from the megacap AI/compute complex — no clean read-through from GPU, memory or datacenter names; this is an AI-application story tied to healthcare-SMB IT budgets.\n- Closest fundamental comps are healthcare-SMB and vertical-software names (Phreesia, Doximity, Tebra-style front-office software); peer prints and SMB-IT-spend commentary are the confirmation set.\n- Idiosyncratic risk dominates: the swing factor is TrueLark AI monetization and quarterly guide-beats rather than macro beta.",
  "first_seen": "2026-07-15",
  "last_analyzed": "2026-07-20T07:29:00+00:00",
  "last_synthesized": "2026-07-18",
  "last_update_source": "theme_discovery",
  "license": "Content © orbyd. Cite the canonical URL."
}